Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease,[4] plaque psoriasis,[5] seborrheic dermatitis,[6] and atopic dermatitis.[5] It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4).[10] It has anti-inflammatory effects.[10][11][12]
It was approved for medical use in the European Union in 2010,[7] in the United States in 2011,[4] and in Canada in 2017.[1] It is available as a generic medication.[13]
Roflumilast is indicated for the treatment of severe chronic obstructive pulmonary disease (COPD),[4] plaque psoriasis,[5][14] seborrheic dermatitis,[6] and atopic dermatitis,[5][15]
It is used in the prevention of exacerbations (lung attacks) in severe chronic obstructive pulmonary disease (COPD).[3][4][7][8][9]
Common (1–10% incidence) adverse effects include diarrhea, weight loss, nausea, headache, insomnia, decreased appetite, abdominal pain, rhinitis, sinusitis, urinary tract infection, and depression.[4][3][8][9][16]
In June 2010, it was approved in the European Union for severe COPD associated with chronic bronchitis.[7][17] In February 2011, it gained FDA approval in the United States for reducing COPD exacerbations.[18][19]
Lokasi Pengunjung: 52.14.45.84